Boundless Bio, INC Form 4 insider transactions

Boundless Bio CEO Zachary Hornby repriced several stock option grants on August 19, 2024, according to a Form 4 filing with the SEC.

Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., repriced several stock option grants on August 19, 2024, according to a Form 4 filing with the SEC.

Chief Medical Officer of Boundless Bio, Klaus Wagner, repriced several stock option grants on August 19, 2024.

Jami Rubin, CFO of Boundless Bio, reports the repricing and acquisition of stock options in a recent SEC Form 4 filing.

Director Jonathan Lim acquired stock options in Boundless Bio, Inc. on June 20, 2024, under the company's 2024 Incentive Award Plan.

Kristina Burow, a director and 10% owner of Boundless Bio, Inc., reports changes in her beneficial ownership of the company's stock following the company's initial public offering.

Director Jonathan Lim reports the conversion of preferred stock to common stock in Boundless Bio, Inc. following the company's initial public offering.

Following Boundless Bio's initial public offering, several directors and related entities reported changes in their beneficial ownership of the company's common stock due to the conversion of preferred stock and open market purchases.

ARCH Venture Funds converted preferred stock to common stock and purchased additional shares in Boundless Bio's initial public offering, resulting in adjustments to their beneficial ownership.

RA Capital Management and related entities report changes in beneficial ownership of Boundless Bio, Inc. common stock following the company's initial public offering.

Wellington Biomedical Innovation Master Investors converted Series B and C Preferred Stock into Common Stock upon the closing of Boundless Bio's initial public offering on April 2, 2024.

Director Jonathan Lim acquired 13,219 stock options in Boundless Bio, Inc. on March 27, 2024, vesting monthly starting April 27, 2024.

Director Jennifer Lew reports acquisition of stock options in Boundless Bio, Inc.

Christine Brennan, a Director of Boundless Bio, Inc., acquired stock options for 26,438 shares on March 27, 2024.

Kristina Burow, a Director at Boundless Bio, filed a Form 4 disclosing the acquisition of 26,438 stock options on March 27, 2024.

Jami Rubin, CFO of Boundless Bio, Inc., reports the acquisition of stock options.

Zachary Hornby, President and CEO of Boundless Bio, Inc., reports the acquisition of stock options.

James Christensen, a director of Boundless Bio, Inc., acquired stock options on March 27, 2024, according to a Form 4 filing with the SEC.

Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc., reported the acquisition of stock options.

Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., reports the acquisition of stock options.

Klaus Wagner, Chief Medical Officer of Boundless Bio, acquired stock options on March 27, 2024, according to a Form 4 filing with the SEC.

Director Nancy Whiting acquired 13,219 stock options in Boundless Bio, Inc. on March 27, 2024, vesting monthly starting April 27, 2024.

Christian Hassig, Chief Scientific Officer of Boundless Bio, Inc., acquired stock options on March 27, 2024.